This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Ipsen/PeptiMimesis Oncology Peptide Program
Description: Ipsen and PeptiMimesis are developing novel therapeutic peptides in oncology. Ipsen will combine its expertise in peptide design and development with PeptiMimesis knowledge in the identification of transmembrane peptides and intracellular signaling.
Ipsen and PeptiMimesis
In March 2016, Ipsen and PeptiMimesis announced the signature of a research partnership and a licensing option for the development and marketing of novel therapeutic peptides in oncology. Under the terms of the agreement, Ipsen and PeptiMimesis will work closely together to move the project forward towards clinical development. PeptiMimesis will receive financial support from Ipsen for the research phases, as well as milestone payments associated to the program. In the event the option is exercised, Ipsen could make further potential payments to PeptiMimesis at development, regulatory and commercial milestones, as well as royalty payments on worldwide annual net sales.
Partners: Ipsen SA
Ipsen/PeptiMimesis Oncology Peptide Program News
Pink Sheet Molecular Insight Acquires Novartis’ Onalta
Additional information available to subscribers only: